{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:37:06Z","timestamp":1753893426166,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 expression and molecular profile with the development of thyroid IRAEs in NSCLC patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Single center, retrospective study including 107 NSCLC patients treated with PD-1\/PD-L1 inhibitors from April 2016 to July 2020. All patients were euthyroid at baseline with at least two TSH measurements post-treatment initiation. The primary outcome was the difference in tumor PD-L1 expression in patients who developed any thyroid IRAEs versus those who remained euthyroid. Additional outcomes included development of overt thyroid dysfunction, the association of specific molecular alterations with thyroid IRAEs, and onset of thyroid IRAEs as a function of tumor PD-L1 expression.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Overall, 37 (34.6%) patients developed any thyroid dysfunction and 18 (16.8%) developed overt thyroid dysfunction. Tumor PD-L1 staining intensity was not associated with thyroid IRAEs. TP53 mutation was less likely to be associated with any thyroid dysfunction (<jats:italic>p<\/jats:italic> &amp;lt; 0.05) and no association was found between EGFR, ROS, ALK or KRAS mutations. There was no association between PD-L1 expression and time to develop thyroid IRAEs.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> PD-L1 expression is not associated with the development of thyroid dysfunction in advanced NSCLC patients treated with ICIs, suggesting that thyroid IRAEs are unrelated to tumor PD-L1 expression.<\/jats:p>","DOI":"10.3389\/pore.2023.1610951","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T04:11:25Z","timestamp":1681704685000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients"],"prefix":"10.3389","volume":"29","author":[{"given":"Adi","family":"Horesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rena","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hovav","family":"Nechushtan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rivka","family":"Dresner-Pollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzahi","family":"Neuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/nejmoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013small-cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/nejmoa1801005","article-title":"Pembrolizumab Plus Chemotherapy in Metastatic Non\u2013small-cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The Spectrum, Incidence, Kinetics and Management of Endocrinopathies with Immune Checkpoint Inhibitors for Metastatic Melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid Abnormalities Following the Use of Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death Receptor Protein-1 Inhibitors in the Treatment of Melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/cancers13061464","article-title":"Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (Icis): Outcomes in a Multiethnic Urban Cohort","volume":"13","author":"D\u2019aiello","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1200\/jco.2020.38.5_suppl.98","article-title":"The Real-World Incidence of Immunotherapy-Related Thyroid Dysfunction: A Retrospective Analysis of a Single center\u2019s Experience over Five Years","volume":"38","author":"Brody","year":"2020","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/j.cllc.2020.01.003","article-title":"Association between Early Immune-Related Adverse Events and Clinical Outcomes in Patients with Non\u2013small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors","volume":"21","author":"Hosoya","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.cllc.2020.06.010","article-title":"Immune-related Adverse Events of Pembrolizumab in a Large Real-World Cohort of Patients with NSCLC with a PD-L1 Expression \u2265 50% and Their Relationship with Clinical Outcomes","volume":"21","author":"Cortellini","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2019.12.014","article-title":"Immune-related Adverse Events Correlate with Clinical Outcomes in NSCLC Patients Treated with Nivolumab: The Italian NSCLC Expanded Access Program","volume":"140","author":"Baldini","year":"2020","journal-title":"Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/1346-8138.13028","article-title":"Serological Aggravation of Autoimmune Thyroid Disease in Two Cases Receiving Nivolumab","volume":"43","author":"Narita","year":"2016","journal-title":"J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T4, and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1210\/JS.2017-00432","article-title":"Patients with Antithyroid Antibodies Are Prone to Develop Destructive Thyroiditis by Nivolumab: A Prospective Study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated Thyroid Dysfunction during T-Cell Checkpoint Blockade in Patients with Non-small-cell Lung Cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1620","DOI":"10.1210\/CLINEM\/DGAB829","article-title":"Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients without Thyroid Autoantibodies at Baseline","volume":"107","author":"Iwama","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical Effects of Obesity on T Cell Function during Tumor Progression and PD-1 Checkpoint Blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline TSH Level Is Associated with Risk of Anti\u2013PD-1\u2013induced Thyroid Dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocr Pract"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and Efficacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"dgaa458","DOI":"10.1210\/CLINEM\/DGAA458","article-title":"Immune Checkpoint Inhibitor-Induced Thyroid Dysfunction Is Associated with Higher Body Mass Index","volume":"105","author":"Pollack","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"volume-title":"Continue NCCN Guidelines Panel Disclosures NCCN Guidelines Version 7.2021 Non-small Cell Lung Cancer","year":"2021","author":"Ettinger","key":"B20"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/J.JTHO.2016.08.146","article-title":"A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana\u2019s Platform","volume":"11","author":"Neuman","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1089\/THY.2019.0726","article-title":"Overt Thyroid Dysfunction and Anti-thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients","volume":"30","author":"Basak","year":"2020","journal-title":"Thyroid"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.31662\/jmaj.2019-0005","article-title":"Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-Related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab","volume":"3","author":"Sugisaka","year":"2019","journal-title":"JMA J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment-related Adverse Events Predict Improved Clinical Outcome in Nsclc Patients on KEYNOTE-001 at a Single center","volume":"6","author":"Lisberg","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II Trial of Atezolizumab as First-Line or Subsequent Therapy for Patients with Programmed Death-Ligand 1-Selected Advanced Non-small-cell Lung Cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1146\/ANNUREV-PATHOL-042320-025840","article-title":"A Balancing Act: P53 Activity from Tumor Suppression to Pathology and Therapeutic Implications","volume":"17","author":"Wang","year":"2021","journal-title":"Review"},{"key":"B27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nrc992","article-title":"The Role of P53 in Determining Sensitivity to Radiotherapy","volume":"3","author":"Gudkov","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/J.CELREP.2019.12.028","article-title":"Cancer-Specific Loss of P53 Leads to a Modulation of Myeloid and T Cell Responses","volume":"30","author":"Blagih","year":"2020","journal-title":"Cell Rep"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1610951\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T04:11:28Z","timestamp":1681704688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1610951\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":28,"alternative-id":["10.3389\/pore.2023.1610951"],"URL":"https:\/\/doi.org\/10.3389\/pore.2023.1610951","relation":{},"ISSN":["1532-2807"],"issn-type":[{"type":"electronic","value":"1532-2807"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"article-number":"1610951"}}